PMID- 30791838
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20211204
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 13
IP  - 1
DP  - 2019 Jan
TI  - Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in 
      patients with renal impairment and HCV: an Egyptian cohort.
PG  - 89-93
LID - 10.1080/17474124.2019.1544070 [doi]
AB  - BACKGROUND: The present study aimed at evaluation of changes in estimated 
      glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients 
      with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of 
      ritonavir-boosted paritaprevir, ombitasvir plus ribavirin. METHODS: Changes in 
      renal functions were compared across follow up time points (baseline, SVR4, and 
      SVR8). Data on on-treatment adverse events (AEs), serious AEs, laboratory 
      abnormalities, treatment discontinuation were collected. RESULTS: 171 patients 
      were included (females 35%, mean age 53 years). 29 patients had liver cirrhosis. 
      The most common etiologies of CKD were diabetes and/or hypertension (n = 67). All 
      included patient reached the end of treatment (EOT) with no treatment 
      discontinuations. The overall EOT response was 100%. 122/122 (100%) patients who 
      reached 4 weeks post-treatment have achieved SVR4, and 80/80 (100%) have achieved 
      SVR12. No reported SAEs. Ribavirin therapy was interrupted in 25% (43/171) of 
      patients due to anemia; 16 patients required blood transfusions. The median eGFR 
      improved from 33.5 (15) mL/min/1.73 m(2) at baseline to 35 (36) mL/min/1.73 m2 at 
      SVR8 (p = 0.0003). CONCLUSIONS: The use of ombitasvir, paritaprevir, and 
      ritonavir for treatment of HCV-infected patients with advanced renal disease was 
      safe and effective, moreover, it was associated with significantly improved eGFR.
FAU - Said, Mohamed
AU  - Said M
AD  - a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , 
      Cairo University , Cairo , Egypt.
FAU - Omar, Heba
AU  - Omar H
AUID- ORCID: 0000-0002-9707-1141
AD  - a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , 
      Cairo University , Cairo , Egypt.
FAU - Soliman, Zeinab
AU  - Soliman Z
AD  - a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , 
      Cairo University , Cairo , Egypt.
FAU - Saad, Yasmin
AU  - Saad Y
AD  - a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , 
      Cairo University , Cairo , Egypt.
FAU - Dabes, Hosam
AU  - Dabes H
AD  - b Internal Medicine Department , Damanhour Medical National Institute , Damanhour 
      , Egypt.
FAU - Hamed, Sozan
AU  - Hamed S
AD  - b Internal Medicine Department , Damanhour Medical National Institute , Damanhour 
      , Egypt.
FAU - ElSaeed, Kadri
AU  - ElSaeed K
AD  - c Internal Medicine Department, Faculty of Medicine , Ain Shams University , 
      Cairo , Egypt.
FAU - ElShazly, Yehia
AU  - ElShazly Y
AD  - c Internal Medicine Department, Faculty of Medicine , Ain Shams University , 
      Cairo , Egypt.
FAU - ElSerafy, Magdi
AU  - ElSerafy M
AD  - a Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine , 
      Cairo University , Cairo , Egypt.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Anilides)
RN  - 0 (Antiviral Agents)
RN  - 0 (Carbamates)
RN  - 0 (Cyclopropanes)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Macrocyclic Compounds)
RN  - 0 (Sulfonamides)
RN  - 2302768XJ8 (ombitasvir)
RN  - 49717AWG6K (Ribavirin)
RN  - 9DLQ4CIU6V (Proline)
RN  - HG18B9YRS7 (Valine)
RN  - OU2YM37K86 (paritaprevir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anilides/adverse effects/*therapeutic use
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Carbamates/adverse effects/*therapeutic use
MH  - Cyclopropanes
MH  - Drug Therapy, Combination
MH  - Egypt
MH  - Female
MH  - Genotype
MH  - *Glomerular Filtration Rate
MH  - Hepacivirus/*drug effects/genetics
MH  - Hepatitis C, Chronic/complications/diagnosis/*drug therapy/virology
MH  - Humans
MH  - Kidney/*physiopathology
MH  - Lactams, Macrocyclic
MH  - Macrocyclic Compounds/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Proline/analogs & derivatives
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Renal Dialysis
MH  - Renal Insufficiency, Chronic/complications/diagnosis/*physiopathology/therapy
MH  - Ribavirin/adverse effects/*therapeutic use
MH  - Sulfonamides
MH  - Sustained Virologic Response
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valine
MH  - Viral Load
MH  - Young Adult
OTO - NOTNLM
OT  - HCV
OT  - chronic kidney disease
OT  - eGFR
OT  - genotype 4
OT  - ombitasvir
OT  - real-world
OT  - ritonavir-boosted paritaprevir
EDAT- 2019/02/23 06:00
MHDA- 2019/07/17 06:00
CRDT- 2019/02/23 06:00
PHST- 2019/02/23 06:00 [entrez]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
AID - 10.1080/17474124.2019.1544070 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):89-93. doi: 
      10.1080/17474124.2019.1544070. Epub 2018 Nov 13.